Screener
Ionis Pharmaceuticals IONS Royalty — Revenue
Other product segments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Ionis Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax.
The source filing: Ionis Pharmaceuticals’s 10-Q, filed July 29, 2026.
- Filed
- Jul 29, 2026, 5:05 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0000874015-26-000251
| Line item | Three Months Ended / June 30, 2026 | Three Months Ended / June 30, 2025 | Six Months Ended / June 30, 2026 | Six Months Ended / June 30, 2025 |
|---|---|---|---|---|
| Revenue: | ||||
| Commercial revenue: | ||||
| Product sales, net | $$31,139 | $19,273 | $74,094 | 25,561 |
| Royalty revenue | 75,958 | 69,952 | 134,282 | 134,117 |
| Other commercial revenue | 11,526 | 13,531 | 18,058 | 19,246 |
| Total commercial revenue | 118,623 | 102,756 | 226,434 | 178,924 |
| Research and development revenue: | ||||
| Collaborative agreement revenue | 133,137 | 336,921 | 253,797 | 381,951 |
ITEM 1. FINANCIAL STATEMENTS
FAQ
- What is Ionis Pharmaceuticals's royalty — revenue?
- Ionis Pharmaceuticals (IONS) reported royalty — revenue of $75.96M in Q2 2026.
- How has Ionis Pharmaceuticals's royalty — revenue changed year-over-year?
- Ionis Pharmaceuticals's royalty — revenue increased by 8.6% year-over-year, from $69.95M to $75.96M.
- What is the long-term trend for Ionis Pharmaceuticals's royalty — revenue?
- Over 2 years (2023 to 2025), Ionis Pharmaceuticals's royalty — revenue has grown at a 2.3% compound annual growth rate (CAGR), from $272.8M to $285.53M.
- What does royalty — revenue mean?
- This metric represents the gross revenue recognized from royalty payments earned through the licensing of intellectual property and proprietary technology to third-party partners. It reflects the commercial success of drugs developed by the company but marketed and sold by external collaborators. This stream is a critical indicator of the company's ability to monetize its R&D pipeline without incurring the full costs of commercialization.
Ask your AI about Ionis Pharmaceuticals's royalty — revenue.
Connect your AI assistant and compare segments, right in your chat.
Connect your AI
Claude